Aldosterone Synthase Inhibitors and Mineralocorticoid Receptor Antagonists: Competitors or Collaborators?

HomeCirculationVol. 149, No. 6Aldosterone Synthase Inhibitors and Mineralocorticoid Receptor Antagonists: Competitors or Collaborators? No AccessArticle CommentaryRequest AccessFull TextAboutView Full TextView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toNo AccessArticle CommentaryRequest AccessFull TextAldosterone Synthase Inhibitors and Mineralocorticoid Receptor Antagonists: Competitors or Collaborators? Bertram Pitt and Gordon H. Williams Bertram PittBertram Pitt https://orcid.org/0000-0001-7703-0345 Department of Medicine, School of Medicine, University of Michigan, Ann Arbor (B.P.). and Gordon H. WilliamsGordon H. Williams Correspondence to: Gordon H. Williams, MD, Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, 221 Longwood Ave, Boston, MA 02115. Email E-mail Address: [email protected] https://orcid.org/0000-0002-4804-1093 Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (G.H.W.). Originally published5 Feb 2024https://doi.org/10.1161/CIRCULATIONAHA.123.066314Circulation. 2024;149:414–416FootnotesFor Sources of Funding and Disclosures, see page 415.The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.Circulation is available at www.ahajournals.org/journal/circCorrespondence to: Gordon H. Williams, MD, Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, 221 Longwood Ave, Boston, MA 02115. Email gwilliams@bwh.harvard.eduREFERENCES1. Brown JM, Siddiqui M, Calhoun DA, Carey RM, Hopkins PN, Williams GH, Vaidya A. The unrecognized prevalence of primary aldosteronism: a cross-sectional study.Ann Intern Med. 2020; 173:10–20. doi: 10.7326/M20-0065CrossrefMedlineGoogle Scholar2. Bauersachs J, Jaisser F, Toto R. Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal disease.Hypertension. 2015; 65:257–263. doi: 10.1161/HYPERTENSIONAHA.114.04488LinkGoogle Scholar3. Ding K, Li Z, Lu Y, Sun L. Efficacy and safety assessment of mineralocorticoid receptor antagonists in patients with chronic kidney disease.Eur J Intern Med. 2023; 115:114–127. doi: 10.1016/j.ejim.2023.05.038CrossrefMedlineGoogle Scholar4. Freeman MW, Halvorsen Y-D, Marshall W, Pater M, Isaacsohn J, Pearce C, Murphy B, Alp N, Srivastava A, Bhatt DL, et al; BrigHTN Investigators. Phase 2 trial of baxdrostat for treatment-resistant hypertension.N Engl J Med. 2023; 388:395–405. doi: 10.1056/NEJMoa2213169CrossrefMedlineGoogle Scholar5. Treesaranuwattana T, Wong KYH, Brooks DL, Tay CS, Williams GH, Williams JS, Pojoga LH. Lysine-specific demethylase-1 deficiency increases agonist signaling via the mineralocorticoid receptor.Hypertension. 2020; 75:1045–1053. doi: 10.1161/HYPERTENSIONAHA.119.13821LinkGoogle Scholar eLetters(0) eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate. Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page. Sign In to Submit a Response to This Article Previous Back to top Next FiguresReferencesRelatedDetails February 6, 2024Vol 149, Issue 6 Advertisement Article Information Metrics © 2024 American Heart Association, Inc.https://doi.org/10.1161/CIRCULATIONAHA.123.066314PMID: 38315762 Originally publishedFebruary 5, 2024 Keywordsaldosteronecytochrome P-450 CYP11B2hypertensionreceptors, mineralocorticoidPDF download Advertisement Subjects Hypertension